This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Mayordomo JL, Lopez Pousa A, Arocho R, Doan QV, Dubois RW, Liu Z.Primary prophylaxis with pegfilgrastim is cost-saving compared with filgrastim for breast cancer in Spain. Value in Health 9: A277 (plus poster) abstr. PCN6, No. 6, Nov-Dec 2006
Booth P, duBois R, Doan QV, Liu Z.Cost utility analysis of primary prophylaxis with pegfilgrastim versus filgrastim for breast cancer in the UK. Value in Health 9: A289 (plus poster) abstr. PCN44, No. 6, Nov-Dec 2006
Goertz A, duBois R, Doan QV, Liu Z, Heissel A, von Minckwitz G.Primary prophylaxis against febrile neutropenia with pegfilgrastim is more cost-effective than filgrastim in women with breast cancer receiving chemotherapy in Germany. Value in Health 9: A300 (plus poster) abstr. PIN6, No. 6, Nov-Dec 2006
Bogillot O, duBois R, Doan QV, Liu Z, Heissel A, Di Palma M.Pegfilgrastim primary prophylaxis is more cost-effective than filgrastim in women with breast cancer receiving chemotherapy in France. Value in Health 9: A283 (plus poster) abstr. PCN24, No. 6, Nov-Dec 2006
Chiroli S, Dubois RW, Doan QV, Liu Z, Heissel A, Palmeri S, Danova M.Cost effectiveness of primary prophylaxis with pegilgrastim or filgrastim in the medical treatment of breast cancer in Italy. Value in Health 9: A280-A281 (plus poster) abstr. PCN17, No. 6, Nov-Dec 2006
Rights and permissions
About this article
Cite this article
Pegfilgrastim fits the bill for febrile neutropenia prophylaxis in Europe. Pharmacoecon. Outcomes News 517, 3–4 (2006). https://doi.org/10.2165/00151234-200605170-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200605170-00004